Marina Posts Drop in Q2 Losses | GenomeWeb

Marina Posts Drop in Q2 Losses

Premium

Marina Biotech, formerly MDRNA, reported this month a drop in second-quarter losses amid a 12 percent declined in expenses.

For the three-month period ended June 30, Marina's net loss fell to $4.1 million, or $0.34 per share, from a year-ago loss of $7.5 million, or $0.84 per share.

Revenues in the quarter slipped to $200,000 from $300,000, but this decrease was more than offset by a dip in research and development spending to $7.4 million from $8.5 million. Selling, general, and administrative costs, however, rose 10 percent to $4.8 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.